← 返回前沿论文

Lnk 调控黑色素瘤中 CD8(+) T 细胞的趋化因子导向的转运

英文原题:Lnk Governs chemokine-directed trafficking of CD8(+) T cells in melanoma.

PubMed 2026/07/01(内容时间) Mol Ther Oncol Q1 · IF 8.5(JCR 2025)

研究概要

Lnk是一种衔接蛋白,在造血和免疫细胞中减弱细胞因子受体信号传导,但其在实体瘤内CD8+ T细胞行为中的作用尚不明确。

中文摘要

Lnk是一种衔接蛋白,可减弱造血和免疫细胞中的细胞因子受体信号传导,但其在实体瘤内CD8+ T细胞行为中的作用尚未明确。我们利用小鼠黑色素瘤模型,比较了Lnk缺陷小鼠与野生型对照组的肿瘤生长和免疫浸润情况,并评估了CD8+ T细胞向黑色素瘤细胞产生的趋化因子信号的迁移。Lnk缺陷小鼠形成的肿瘤较小,且瘤内CD8+细胞毒性T细胞数量更多。两组间的肿瘤趋化因子谱相当,包括CXCL2等白细胞介素-8家族信号的高水平表达,但缺乏Lnk的CD8+ T细胞在离体条件下向黑色素瘤来源信号的迁移增强,并在体内更有效地在肿瘤内积聚。药理学抑制CXCR1/2消除了这种迁移优势。在白细胞介素-8家族趋化因子刺激下,Lnk缺陷的CD8+ T细胞表现出STAT3和ERK信号通路激活增强。此外,反义介导的野生型T细胞中Lnk下调,在过继转移至野生型宿主后,导致其在黑色素瘤肿瘤内的积聚增强。这些发现表明Lnk是黑色素瘤中CD8+ T细胞CXCR1/2依赖性运输的负调控因子,并提示调节这一细胞内检查点可能改善T细胞向实体瘤的运输并增强过继性细胞免疫疗法的效果。

展开英文摘要原文

Lnk is an adaptor protein that attenuates cytokine receptor signaling in hematopoietic and immune cells, but its role in the behavior of CD8 + T cells within solid tumors is not well defined. Using a murine melanoma model, we compared tumor growth and immune infiltration in Lnk-deficient mice and in wild-type controls and evaluated CD8 + T cell trafficking toward chemokine signals produced by melanoma cells. Lnk-deficient mice developed smaller tumors containing greater numbers of intratumoral CD8 + cytotoxic T cells. Tumor chemokine profiles, including high levels of interleukin-8 family signals such as CXCL2, were comparable between groups, yet CD8 + T cells lacking Lnk showed enhanced migration toward melanoma-derived cues ex vivo and accumulated more effectively within tumors in vivo . Pharmacologic inhibition of CXCR1/2 abolished this migratory advantage. Upon stimulation with interleukin-8 family chemokines, Lnk-deficient CD8 + T cells exhibited increased activation of STAT3 and ERK signaling pathways. Moreover, antisense-mediated downregulation of Lnk in wild-type T cells resulted in enhanced accumulation within melanoma tumors following adoptive transfer into wild-type hosts. These findings identify Lnk as a negative regulator of CXCR1/2-dependent trafficking of CD8 + T cells in melanoma and suggest that modulating this intracellular checkpoint may improve T cell trafficking into solid tumors and enhance the effectiveness of adoptive cellular immunotherapies.

论文信息

作者
Derdikman Ofir Y、Aswad M、Hayun M、Pechkovsky A、Kheshaiboun G、Ghanayiem N、Khier Y、Zohar Y
第一作者单位
Section of Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.United States
通讯作者单位
The Clinical Research Institute at RAMBAM (CRIR), Rambam Health Care Campus, Haifa 3109601, Israel.Israel
期刊
Molecular therapy. Oncology2026 Sep 17
原文标识
PubMed 42519390 · DOI 10.1016/j.omton.2026.201288